BWM
VRTX icon

Bullock Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bullock Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.9K Hold
50
– – 0.01% 343
2026
Q1 		$22.4K Sell
50
-5
-9% -$2.33K 0.01% 340
2025
Q4 		$24.9K Hold
55
– – 0.01% 320
2025
Q3 		$22.2K Buy
55
+5
+10% +$2.09K 0.01% 336
2025
Q2 		$22.6K Sell
50
-58
-54% -$26.7K 0.01% 309
2025
Q1 		$52.4K Hold
108
– – 0.03% 237
2024
Q4 		$43.5K Sell
108
-18
-14% -$8.34K 0.03% 264
2024
Q3 		$59.2K Hold
126
– – 0.04% 221
2024
Q2 		$59.4K Sell
126
-13
-9% -$5.64K 0.04% 220
2024
Q1 		$58.4K Buy
+139
New +$58.8K 0.04% 233

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Bullock Wealth Management's VRTX Position: Q2 2026 in Review

Bullock Wealth Management held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 50 shares worth $24.9K. The position accounts for 0.01% of the portfolio, ranked #343.

Bullock Wealth Management first reported a position in VRTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $59.4K in Q2 2024. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Bullock Wealth Management held 50 shares of Vertex Pharmaceuticals worth $24.9K as of Q2 2026.
  • Bullock Wealth Management left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
  • Vertex Pharmaceuticals made up 0.01% of Bullock Wealth Management's portfolio in Q2 2026, its #343 holding.
  • Bullock Wealth Management first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • Bullock Wealth Management's Vertex Pharmaceuticals position peaked at $59.4K in Q2 2024.
  • 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Bullock Wealth Management's 13F filing for Q2 2026, filed 19 Aug 2026.